Replimune seeks third FDA approval attempt, Pfizer signs China deal, panel backs updated Covid vaccine

Replimune is pursuing a third attempt to secure FDA approval for its investigational therapy, after two prior submissions did not succeed.

Pfizer has entered into a new agreement to expand its presence in the Chinese market, though details of the partnership were not disclosed.

An FDA advisory panel has recommended that the upcoming fall COVID‑19 vaccine be updated to target the emerging XFG variant, signaling a potential shift in the vaccine strategy for the coming season.